Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss

scientific article published on 4 August 2016

Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1681/ASN.2016030368
P932PMC publication ID5280026
P698PubMed publication ID27493255

P50authorDewi VernereyQ116878139
Adriana ZeeviQ64123938
P2093author name stringXavier Jouven
Christophe Legendre
Alexandre Loupy
Carmen Lefaucheur
Jean-Paul Duong van Huyen
Olivier Aubert
Denis Glotz
Denis Viglietti
Carol Bentlejewski
Clément Gosset
P2860cites workFactors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After DesensitizationQ86568728
Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantationQ86932430
C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot StudyQ86955576
Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney RecipientsQ87006000
Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipientsQ87395286
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyondQ29614697
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupQ29614889
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantationQ34124202
Subgroup analyses in randomized controlled trials: the need for risk stratification in kidney transplantationQ34382549
Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.Q35027253
Humoral theory of transplantationQ35142603
Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney AllograftsQ35790552
Anti-HLA antibody analysis and crossmatching in heart and lung transplantationQ35808818
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersQ35927436
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated InjuryQ36417907
Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.Q36514864
Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipientsQ36772957
Subclass analysis of donor HLA-specific IgG in antibody-incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure.Q37155993
Update on Alloantibodies in Solid Organ TransplantationQ38568370
Banff 07 classification of renal allograft pathology: updates and future directionsQ40121163
Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information.Q40990548
The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantationQ41150961
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing.Q41228171
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratificationQ43674377
Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipientsQ43681319
Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsiesQ43772409
Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantationQ44557532
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesionsQ45342440
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantationQ45627897
Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.Q46060462
Complement-binding anti-HLA antibodies and kidney-allograft survivalQ46141053
Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation.Q46174297
Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantationQ46270876
Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survivalQ47331305
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejectionQ47869308
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.Q48005087
The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patientsQ48397261
The Banff 97 working classification of renal allograft pathologyQ59314413
The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibodyQ68076654
The limitations of risk factors as prognostic toolsQ79445507
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)Q83101436
HLA antibody detection and characterization by solid phase immunoassays: methods and pitfallsQ84291597
P433issue2
P304page(s)702-715
P577publication date2016-08-04
P1433published inJournal of the American Society of NephrologyQ17123893
P1476titleValue of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss
P478volume28

Reverse relations

cites work (P2860)
Q64067275A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation
Q33865743An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
Q39366396Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
Q39445381Application, technical issues, and interpretation of C1q for graft outcome
Q54589598Assignment of C1q-binding HLA antibodies as unacceptable HLA antigens avoids positive CDC-crossmatches prior to transplantation of deceased donor organs.
Q90265882CXCR5+PD1+ICOS+ Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation
Q37641415Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine
Q90428801Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients
Q55509898Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome.
Q54969814Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.
Q58488462Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure
Q38861456De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.
Q101038727Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation
Q47563660Desensitisation strategies in high-risk children before kidney transplantation.
Q49719376Differential effects of donor-specific HLA antibodies in living- versus deceased-donor transplantation.
Q39265221Donor-Specific Antibodies in Kidney Transplant Recipients
Q92803508Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure
Q89746966Evaluation and Treatment of Acute Rejection in Kidney Allografts
Q39366464Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans
Q37590820From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.
Q52373711HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection.
Q64113679HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway
Q58559130Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies
Q64899061Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation.
Q92558904Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies
Q47595221T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
Q30397251The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies
Q101131721The challenge of using the virtual crossmatch as a singular tool for the detection of Anti-HLA antibodies- A study from a tertiary care institute from South India
Q50504222Utility of protocol kidney biopsies for de novo donor-specific antibodies.
Q89049434Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation